Browse by Glasgow Author (original) (raw)

Number of items: 39.

2025

Hardy-Bessard, A.-C. et al. (2025)Dostarlimab and niraparib in primary advanced ovarian cancer. Annals of Oncology, 36(12), pp. 1503-1513. (doi: 10.1016/j.annonc.2025.05.009) (PMID:40461381)

2023

Corbaux, P. et al. (2023)Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis. European Journal of Cancer, 191, 112966. (doi: 10.1016/j.ejca.2023.112966) (PMID:37542936)

Banerjee, S. et al. (2023)Efficacy and safety of weekly paclitaxel plus vistusertib vs paclitaxel alone in patients with platinum-resistant ovarian high-grade serous carcinoma: the OCTOPUS multicenter, phase 2, randomized clinical trial. JAMA Oncology, 9(5), pp. 675-682. (doi: 10.1001/jamaoncol.2022.7966) (PMID:36928279) (PMCID:PMC10020933)

Karamouza, E. et al. (2023)CA-125 early dynamics to predict overall survival in women with newly diagnosed advanced ovarian cancer based on meta-analysis data. Cancers, 15(6), 1823. (doi: 10.3390/cancers15061823) (PMID:36980708) (PMCID:PMC10047009)

Sundar, S. et al. (2023)British Gynaecological Cancer Society recommendations for evidence based, population data derived quality performance indicators for ovarian cancer. Cancers, 15(2), 337. (doi: 10.3390/cancers15020337) (PMID:36672287) (PMCID:PMC9856668)

2022

Ho, G.-Y. et al. (2022)Epithelial-to-mesenchymal transition supports ovarian carcinosarcoma tumorigenesis and confers sensitivity to microtubule-targeting with eribulin. Cancer Research, 82(23), pp. 4457-4473. (doi: 10.1158/0008-5472.can-21-4012) (PMID:36206301) (PMCID:PMC9716257)

Konstantinopoulos, P. A. et al. (2022)EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study). Future Oncology, 18(31), pp. 3481-3492. (doi: 10.2217/fon-2022-0666) (PMID:36066851)

Cummins, C. et al. (2022)Investigating the impact of ultra-radical surgery on survival in advanced ovarian cancer using population-based data in a multicentre UK study. Cancers, 14(18), 4362. (doi: 10.3390/cancers14184362) (PMID:36139523) (PMCID:PMC9497111)

Glasspool, R. et al. (2022)Modifiable pre-treatment factors are associated with quality of life in women with gynaecological cancers at diagnosis and one year later: results from the HORIZONS UK national cohort study. Gynecologic Oncology, 165(3), pp. 610-618. (doi: 10.1016/j.ygyno.2022.03.012) (PMID:35351333)

Sundar, S. et al. (2022)Quality of life from cytoreductive surgery in advanced Ovarian cancer: investigating association with disease burden and surgical complexity in the international, prospective, SOCQER2 cohort study. BJOG: An International Journal of Obstetrics and Gynaecology, 129(7), pp. 1122-1132. (doi: 10.1111/1471-0528.17041) (PMID:34865316)

Wohlmuth, C. et al. (2022)CA-125 levels are predictive of survival in low-grade serous ovarian cancer—a multicenter analysis. Cancers, 14(8), 1954. (doi: 10.3390/cancers14081954) (PMID:35454861) (PMCID:PMC9024456)

2021

Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319, Hinsley, Samantha ORCID: https://orcid.org/0000-0001-6903-4688, Mcneish, Iain A. ORCID: https://orcid.org/0000-0002-9387-7586, Roxburgh, Patricia ORCID: https://orcid.org/0000-0001-9869-591X and Glasspool, Rosalind(2021)Metronomic oral cyclophosphamide in relapsed ovarian cancer. International Journal of Gynecological Cancer, 31, pp. 1037-1044. (doi: 10.1136/ijgc-2021-002467) (PMID:34016703)

Paterson, K., Zanivan, S. ORCID: https://orcid.org/0000-0002-9880-9099, Glasspool, R., Coffelt, S.B. ORCID: https://orcid.org/0000-0003-2257-2862 and Zagnoni, M.(2021)Microfluidic technologies for immunotherapy studies on solid tumours. Lab on a Chip, 21(12), pp. 2306-2329. (doi: 10.1039/D0LC01305F) (PMID:34085677) (PMCID:PMC8204114)

Ewing, A. et al. (2021)Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high grade serous ovarian carcinoma. Clinical Cancer Research, 27(11), pp. 3201-3214. (doi: 10.1158/1078-0432.CCR-20-4068) (PMID:33741650) (PMCID:PMC7610896)

2020

Talhouk, A. et al. (2020)Development and validation of the gene-expression predictor of high-grade-serous ovarian carcinoma molecular subTYPE (PrOTYPE). Clinical Cancer Research, 26(20), (doi: 10.1158/1078-0432.CCR-20-0103) (PMID:32554541) (PMCID:PMC7572656)

Millstein, J. et al. (2020)Prognostic gene expression signature for high-grade serous ovarian cancer. Annals of Oncology, 31(9), pp. 1240-1250. (doi: 10.1016/j.annonc.2020.05.019) (PMID:32473302) (PMCID:PMC7484370)

Lord, Rosemary, Rauniyar, Jyoti, Morris, Tamsin, Condon, Orlaith, Jones, Rachel, Miller, Rowan, Hall, Marcia, Lofts, Fiona, Glasspool, Rosalind M. and Hudson, Emma(2020)Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors. International Journal of Gynecological Cancer, 30(7), pp. 1026-1033. (doi: 10.1136/ijgc-2019-000973) (PMID:32321768)

Concin, Nicole, Ray-Coquard, Isabelle, Glasspool, Rosalind M., Braicu, Elena, Farrelly, Laura, Votan, Benedicte, Mirza, Mansoor Raza, Gonzalez Martin, Antonio, Vergote, Ignace and Pignata, Sandro(2020)European Network of Gynaecological Oncological Trial Groups’ requirements for trials between academic groups and industry partners – a new Model D for drug and medical device development. International Journal of Gynecologic Cancer, 30(6), pp. 730-734. (doi: 10.1136/ijgc-2020-001464) (PMID:32404377)

Pfisterer, J. et al. (2020)Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncology, 21(5), pp. 699-709. (doi: 10.1016/S1470-2045(20)30142-X) (PMID:32305099)

Rees, Margaret, Angioli, Roberto, Coleman, Robert L., Glasspool, Rosalind, Plotti, Francesco, Simoncini, Tommaso and Terranova, Corrado(2020)European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis. Maturitas, 134, pp. 56-61. (doi: 10.1016/j.maturitas.2020.01.005) (PMID:32059825)

Paoletti, X. et al. (2020)Assessment of progression-free survival as a surrogate end point of overall survival in first-line treatment of ovarian cancer. JAMA Network Open, 3(1), e1918939. (doi: 10.1001/jamanetworkopen.2019.18939) (PMID:31922558) (PMCID:PMC6991254)

2019

Clamp, A. R. et al. (2019)Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet (North American Edition), 394(10214), pp. 2084-2095. (doi: 10.1016/S0140-6736(19)32259-7) (PMID:31791688) (PMCID:PMC6902268)

Cohen, P. A. et al. (2019)Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. Gynecologic Oncology, 154(2), pp. 441-448. (doi: 10.1016/j.ygyno.2019.04.679) (PMID:31118141)

2018

Sassarini, Jenifer, Perera, Mahesh, Spowart, Keith, McAllister, Kay, Fraser, Judith, Glasspool, Ros, Harrand, Rosie, Chitoni, Marina, Stallard, Sheila and Lumsden, Mary-Ann ORCID: https://orcid.org/0000-0003-2998-9185(2018)Managing vulvovaginal atrophy after breast cancer. Post Reproductive Health, 24(4), pp. 163-165. (doi: 10.1177/2053369118805344) (PMID:30348046)

Rust, K. et al. (2018)Routine germline BRCA1 and BRCA2 testing in ovarian carcinoma patients: analysis of the Scottish real life experience. BJOG: An International Journal of Obstetrics and Gynaecology, 125(11), pp. 1451-1458. (doi: 10.1111/1471-0528.15171) (PMID:29460478)

Kelemen, L. E. et al. (2018)rs495139 in the TYMS-ENOSF1 region and risk of ovarian carcinoma of mucinous histology. International Journal of Molecular Sciences, 19(9), 2473. (doi: 10.3390/ijms19092473) (PMID:30134598) (PMCID:PMC6163881)

Dixon-Suen, S. C. et al. (2018)Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer, 118(8), pp. 1123-1129. (doi: 10.1038/s41416-018-0011-3) (PMID:29555990) (PMCID:PMC5931085)

2017

Cooke, S. L. et al. (2017)The driver mutational landscape of ovarian squamous cell carcinomas arising in mature cystic teratoma. Clinical Cancer Research, 23(24), pp. 7633-7640. (doi: 10.1158/1078-0432.CCR-17-1789) (PMID:28954785)

Goranova, T. et al. (2017)Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium. British Journal of Cancer, 116, pp. 1294-1301. (doi: 10.1038/bjc.2017.86) (PMID:28359078) (PMCID:PMC5482731)

Phelan, C. M. et al. (2017)Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 49, pp. 680-691. (doi: 10.1038/ng.3826) (PMID:28346442)

Sucheston-Campbell, L. E. et al. (2017)No evidence that genetic variation in the myeloid-derived suppressor cell pathway influences ovarian cancer survival. Cancer Epidemiology, Biomarkers and Prevention, 26(3), pp. 420-424. (doi: 10.1158/1055-9965.EPI-16-0631) (PMID:27677730) (PMCID:PMC5500198)

Kar, S. P. et al. (2017)Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 116(4), pp. 524-535. (doi: 10.1038/bjc.2016.426) (PMID:28103614) (PMCID:PMC5318969)

2016

Southey, M. C. et al. (2016)PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. Journal of Medical Genetics, 53(12), pp. 800-811. (doi: 10.1136/jmedgenet-2016-103839) (PMID:27595995) (PMCID:PMC5200636)

Lawrenson, K. et al. (2016)Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nature Communications, 7, 12675. (doi: 10.1038/ncomms12675) (PMID:27601076) (PMCID:PMC5023955)

Dixon, S. C. et al. (2016)Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology, 45(3), pp. 884-895. (doi: 10.1093/ije/dyw158) (PMID:27401727) (PMCID:PMC5644573)

Hampras, S. S. et al. (2016)Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 7(43), pp. 69097-69110. (doi: 10.18632/oncotarget.10215) (PMID:27533245)

2015

Johnatty, S. E. et al. (2015)Genome-wide analysis identifies novel loci associated with ovarian cancer outcomes: findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 21(23), pp. 5264-5276. (doi: 10.1158/1078-0432.CCR-15-0632) (PMID:26152742) (PMCID:PMC4624261)

Kar, S. P. et al. (2015)Network-based integration of GWAS and gene expression identifies a HOX-centric network associated with serous ovarian cancer risk. Cancer Epidemiology, Biomarkers and Prevention, 24(10), pp. 1574-1584. (doi: 10.1158/1055-9965.epi-14-1270) (PMID:26209509)

Kelemen, L.E. et al. (2015)Genome-wide significant risk associations for mucinous ovarian carcinoma. Nature Genetics, 47(8), pp. 888-897. (doi: 10.1038/ng.3336) (PMID:26075790) (PMCID:PMC4520768)

This list was generated on Tue Feb 17 05:14:15 2026 GMT.